期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

瑞舒伐他汀对急性冠脉综合征患者颈动脉斑块的作用 被引量：3

Effect of Rosurastain on Carotid Plaques in Patients With Acute Coronary Syndrome
下载PDF
导出
摘要 目的:探讨瑞舒伐他汀对急性冠脉综合征患者颈动脉斑块的影响及机制。方法:对随机70例急性冠脉综合征患者常规治疗外,加用瑞舒伐他汀10mg,每晚1次。治疗6个月后测总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及超敏C反应蛋白(hs-CRP)的水平,采用彩色多普勒测定治疗前后颈动脉内膜的厚度及颈动脉斑块的变化。结果:瑞舒伐他汀治疗后6个月,患者TC、LDL-C、hs-CRP显著低于治疗前水平(P<0.01)。双侧颈动脉内膜厚度及颈动脉斑块缩小程度,与治疗前比较有显著差异(P<0.01)。结论:瑞舒伐他汀通过降低血脂、降低hs-CRP水平,稳定急性冠脉综合征患者颈动脉斑块。 Objective： To explore the effect of rosurastain on carotid plaques in patients with acute coronary syn drome （ACS）. Methods： Seventy cases of ACS received rosurastain 10mg every night on the basis of routine treatment. Serum levels of TC, LDL-C, HDL-C and hs-CRP were measured 6 months after treatment. The intima-media thickness （IMT） and atherosclerotic plaques were measured by means of ultrasound before and 6 months after therapy. Results： Serum levels of TC, LDL-C, hs-CRP dereased significantly （P〈0. 01）and IMT, atherosclerotic plaques decreased 6 months after treatment （P〈0. 01）. Conclusions： Rosurastain can stabilize carotid plaques in ACS by decreasing the serum level of TC, LDL-C and hs-CRP.
作者 曹小织 江丽
机构地区 南京军区福州总医院
出处 《内科急危重症杂志》 2009年第5期240-240,259,共2页 Journal of Critical Care In Internal Medicine
关键词 瑞舒伐他汀 急性冠脉综合征 颈动脉斑块 血脂 HS-CRP Rosurastain Acute coronary syndrome Carotid atherosclerotic plaque Lipid Hs-CRP
分类号 R541.4 [医药卫生—心血管疾病] R972.6 [医药卫生—药品]
  • 相关文献

参考文献7

  • 1Barth JD. An update on carotid ultrasound measurement of intimamedia thickness. Am J Cardiol,2002,89(Suppl) :32.
  • 2Oleary DH, Polak JF, MPH. Carotid artery initima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med, 1999,340: 14.
  • 3吴天歌.冠心病患者超敏C反应蛋白的临床意义及阿司匹林的影响[J].医学理论与实践,2009,22(2):127-128. 被引量：3
  • 4李芳,余素琴,杜艳华.急性冠脉综合征的炎症机制[J].内科急危重症杂志,2007,13(3):159-160. 被引量：3
  • 5Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation,2002,105 : 1135.
  • 6Anders GO. A new stain: a new standard. Clin Cardiol, 2001,24: 18.
  • 7Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathologen. Int J Cardiol,2006,106:291.

二级参考文献23

  • 1王前,郑磊,曾方银.超敏C-反应蛋白的研究现状及临床应用[J].中华检验医学杂志,2004,27(8):542-544. 被引量：193
  • 2Ridker PM, Glynn RJ, Hennekens CH. C- reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction [J]. Circulation, 1998, 97: 2007-2011.
  • 3Torzewski J, Torzewski M, Bowyer DE,et al. C- reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries[J]. Arterioscler Thorn Vasc Biol, 1998, 18 : 1386-1392.
  • 4Libby P,Ridker P,Maseri A.Inflammation and atherosclerosis.Clirculation,2002,105:1135.
  • 5Stemme S,Hansson GK.Immune mechanisms in atherogenesis.Ann Med,1994,26:141.
  • 6Viedt C,Dechend R,Fei J,et al.MCP-1 induces inflammatory activation of human tubular epithelial cells:involvement of the transcription factor,nuclear factor-kappa B and activating protein-1.J Am Soc Nephrol,2002,13:1534.
  • 7Lippy P.Current concepts of the pathogenesis of the acute coronary syndromes.Circulation,2001,104:365.
  • 8Haim M,Tanne D,Boyko V,et al.Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with choronic coronary heart disease.J AM Coll Cardiol,2002,39:1133.
  • 9Mulvihill NT,Foley JB,Murphy RT,et al.Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules.Heart,2001,85:623.
  • 10Atalar E,Aytemir K,Haznedaroglu I,et al.Increased plasma levels of soluble selectins in pations with unstable angina.Int J Cardiol,2001,78:69.

共引文献4

同被引文献25

  • 1Sillesen H. Statins and their use in preventing carotid disease [J]. Curr Atheroscler Rep,2009,11(4) : 309-314.
  • 2Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of apoB/ AI, total cholesterol /HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT TIMI 22 [J]. Arterioscler Thromh Vasc Bio1,2009,29(3):424-430.
  • 3Ballantyne CM, Raiehlen JS, Nicholis SJ, et al. Effect of rosuvas- tatin therapy on coronary artery stenoses assessed by quantita- tive coronary angiography: a study to evaluate the effect of rosu- vastatin on intravascular ultrasound- derived coronary athero ma burden[J]. Circulation, 2008,117 (19) : 2458-2466.
  • 4Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatlon to prevent vascular events in men and women with elevated C-reac- tive protein[J]. N Engl J Med,2008,359(21) :2195- 2207.
  • 5Everett BM, Glynn RJ, MacFadyen JG,et al. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: iustification for the Use of Statins in Pre- vention: an Intervention Trial Evaluating Rosuvastatin(JUPl- TER )[J]. Circulation, 2010, 121 ( 1 ) : 143-150.
  • 6Mora S,Glynn R J, Hsia J,et al. Statins for the primary preven- tion of cardiovascular events in women with elevated high-sensi tivity C reactive protein or dyslipidemia:results from the Justifi- cation for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin ( JUPITER ) and meta-analysis of women from primary prevention trials[J]. Circulation, 2010,121 (9) : 1069-1077.
  • 7Peters SA,Palmer MK, Grobbee DE, et al. C-reactive protein lowering with rosuvastatin in the METEOR study[J]. J Intern Med,2010,268(2) : 155-161.
  • 8Haddad RM, Ballantyne CM. METEOR Trial reports on the effect of rosuvastatin on progression of carotid intima media thickness in low risk individuals with subclinical atherosclerosis [J]. Phys Sportsmed, 2010,38(2) : 180-182.
  • 9王春雪,王拥军.他汀类药物治疗缺血性脑血管病新理论与实践[J].中国实用内科杂志,2009,29(1):12-14. 被引量：15
  • 10曹小织,江丽.瑞舒伐他汀对急性冠脉综合征患者颈动脉斑块的影响[J].中国误诊学杂志,2009,9(17):4062-4063. 被引量：2

引证文献3

二级引证文献6

内科急危重症杂志
2009年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部